Search

Your search keyword '"Lokhorst, A. M."' showing total 75 results
Start Over Author "Lokhorst, A. M." Publication Type Electronic Resources
75 results on '"Lokhorst, A. M."'

1. Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma:Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial

Author

Mai, Elias K., Nogai, Axel, Lokhorst, Henk M., van der Holt, Bronno, Zweegman, Sonja, Weisel, Katja C., Croockewit, Sandra, Jauch, Anna, Hillengass, Jens, Stevens-Kroef, Marian, Raab, Marc S., Broijl, Annemiek, Bos, Gerard M.J., Brossart, Peter, Ypma, Paula, Hanoun, Christine, Bertsch, Uta, Hielscher, Thomas, Salwender, Hans J., Scheid, Christoph, Goldschmidt, Hartmut, Sonneveld, Pieter, Mai, Elias K., Nogai, Axel, Lokhorst, Henk M., van der Holt, Bronno, Zweegman, Sonja, Weisel, Katja C., Croockewit, Sandra, Jauch, Anna, Hillengass, Jens, Stevens-Kroef, Marian, Raab, Marc S., Broijl, Annemiek, Bos, Gerard M.J., Brossart, Peter, Ypma, Paula, Hanoun, Christine, Bertsch, Uta, Hielscher, Thomas, Salwender, Hans J., Scheid, Christoph, Goldschmidt, Hartmut, and Sonneveld, Pieter

Published
2024

2. Safety and effectiveness of surgical excision of medium, large, and giant congenital melanocytic nevi:A systematic review and meta-analysis

Author

Gout, H. Antoine, Fledderus, Anne C., Lokhorst, Max M., Pasmans, Suzanne G.M.A., Breugem, Corstiaan C., Lapid, Oren, van der Horst, Chantal M.A.M., Gout, H. Antoine, Fledderus, Anne C., Lokhorst, Max M., Pasmans, Suzanne G.M.A., Breugem, Corstiaan C., Lapid, Oren, and van der Horst, Chantal M.A.M.

Abstract

Background: Treatment indications of congenital melanocytic naevi (CMN) have shifted from the prevention of malignant transformation more towards the improvement of appearance and psychosocial health. Surgical excision is often preferred, but its safety and effectiveness remain unclear. Objective: To assess the outcomes of surgical excision of medium-to-giant CMN. Primary outcome: safety (complications). Secondary outcome: effectiveness (satisfaction and CMN core outcomes). Methods: PubMed, EMBASE, and CENTRAL were searched for studies on the excision of medium-to-giant CMN and/or CMN requiring reconstruction or serial excision. Meta-analyses of safety per patient were conducted, and pooled outcomes of safety and effectiveness were presented in summary-of-findings tables. Results: A total of 1444 studies were found, of which 22 were included, evaluating 643 eligible patients. Study quality varied, and reporting of baseline characteristics and outcomes was heterogeneous. Pooled proportions were overall 9.8% for major wound-related complications, 1.2% for minor wound-related complications, 1.2% for scar-related complications, and 4.3% for anatomical deformities. For large/giant CMN, complication rates were, respectively, 23.1%, 2.9%, 12.9%, and 2.4%; and for CMN with eyelid involvement, 0.5%, 3.3%, 0.4%, and 54.2%. Patients rated their satisfaction with the cosmetic outcome as 24.4% excellent, 71.0% good, and 4.6% poor/moderate. Physicians rated this as 18.3% excellent, 70.1% good, and 11.7% poor/moderate. Thirty-five other outcomes of effectiveness were summarized. However, many were rarely reported. Conclusions: Surgical excision of CMN appears to be safe and effective in many cases, depending on CMN size and location. Major wound-related complications and scar-related complications occurred more frequently with large/giant CMN, whereas anatomical deformities occurred with the majority of CMN with eyelid involvement.

Published
2023

3. The pathfinder Dragonfly Spectral Line Mapper: Pushing the limits for ultra-low surface brightness spectroscopy

Author

Lokhorst, Deborah M., Chen, Seery, Pasha, Imad, Shen, Jeff, Malakhov, Evgeni I., Abraham, Roberto G., van Dokkum, Pieter, Lokhorst, Deborah M., Chen, Seery, Pasha, Imad, Shen, Jeff, Malakhov, Evgeni I., Abraham, Roberto G., and van Dokkum, Pieter

Abstract

The pathfinder Dragonfly Spectral Line Mapper is a distributed aperture telescope based off of the Dragonfly Telephoto Array with additional instrumentation (the Dragonfly "Filter-Tilter") to enable ultranarrow bandpass imaging. The pathfinder is composed of three redundant optical tube assemblies (OTAs) which are mounted together to form a single field of view imaging telescope (where the effective aperture diameter increases as the square-root of the number of OTAs). The pathfinder has been on sky from March 2020 to October 2021 equipped with narrowband filters to provide proof-of-concept imaging, surface brightness limit measurements, on sky testing, and observing software development. Here we describe the pathfinder telescope and the sensitivity limits reached along with observing methods. We outline the current limiting factors for reaching ultra-low surface brightnesses and present a comprehensive comparison of instrument sensitivities to low surface brightness line emission and other methods of observing the ultra-faint line emission from diffuse gas. Finally, we touch on plans for the upcoming 120-OTA Dragonfly Spectral Line Mapper, which is currently under construction., Comment: 17 pages, 10 figures, published in SPIE

Published
2022
Full Text
View/download PDF

4. Distributed Aperture Telescopes and the Dragonfly Telephoto Array

Author

Abraham, Roberto G., van Dokkum, Pieter G., Lokhorst, Deborah M., Chen, Seery, Liu, Qing, Rice, Michael L., Rice, E. Lynn, Abraham, Roberto G., van Dokkum, Pieter G., Lokhorst, Deborah M., Chen, Seery, Liu, Qing, Rice, Michael L., and Rice, E. Lynn

Abstract

Telescope arrays allow high-performance wide-field imaging systems to be built more quickly and at lower cost than conventional telescopes. Distributed aperture telescopes (the premier example of which is the Dragonfly Telephoto Array) are a special type of array in which all telescopes point at roughly the same position in the sky. In this configuration the array performs like a large and optically very fast single telescope with unusually good control over systematic errors. In a few key areas, such as low surface brightness imaging over wide fields of view, distributed aperture telescopes outperform conventional survey telescopes by a wide margin. In these Proceedings we outline the rationale for distributed aperture telescopes, and highlight the strengths and weaknesses of the concept. Areas of observational parameter space in which the design excels are identified. These correspond to areas of astrophysics that are both relatively unexplored and which have unusually strong breakthrough potential., Comment: Writeup of a talk given at SPIE Astronomical Telescopes + Instrumentation, 2022, Montreal, Quebec, Canada. arXiv admin note: text overlap with arXiv:1612.06415

Published
2022
Full Text
View/download PDF

5. The Dragonfly Spectral Line Mapper: Design and First Light

Author

Chen, Seery, Lokhorst, Deborah M., Shen, Jeff, Pasha, Imad, Malakhov, Evegni I., Abraham, Roberto G., van Dokkum, Pieter, Chen, Seery, Lokhorst, Deborah M., Shen, Jeff, Pasha, Imad, Malakhov, Evegni I., Abraham, Roberto G., and van Dokkum, Pieter

Abstract

The Dragonfly Spectral Line Mapper (DSLM) is the latest evolution of the Dragonfly Telephoto Array, which turns it into the world's most powerful wide-field spectral line imager. The DSLM will be the equivalent of a 1.6m aperture $f$/0.26 refractor with a built-in Integral Field Spectrometer, covering a five square degree field of view. The new telescope is designed to carry out ultra-narrow bandpass imaging of the low surface brightness universe with exquisite control over systematic errors, including real-time calibration of atmospheric variations in airglow. The key to Dragonfly's transformation is the "Filter-Tilter", a mechanical assembly which holds ultra-narrow bandpass interference filters in front of each lens in the array and tilts them to smoothly shift their central wavelength. Here we describe our development process based on rapid prototyping, iterative design, and mass production. This process has resulted in numerous improvements to the design of the DSLM from the initial pathfinder instrument, including changes to narrower bandpass filters and the addition of a suite of calibration filters for continuum light subtraction and sky line monitoring. Improvements have also been made to the electronics and hardware of the array, which improve tilting accuracy, rigidity and light baffling. Here we present laboratory and on-sky measurements from the deployment of the first bank of lenses in May 2022, and a progress report on the completion of the full array in early 2023., Comment: 13 pages, 5 figures, SPIE conference proceedings

Published
2022

6. Development of a condition-specific patient-reported outcome measure for measuring symptoms and appearance in vascular malformations: the OVAMA questionnaire.

Author

UCL - SSS/DDUV/GEHU - Génétique, Lokhorst, M M, Horbach, S E R, Young-Afat, D A, Stor, M L E, Haverman, L, Spuls, P I, van der Horst, C M A M, Boon, Laurence M., OVAMA Steering Group, UCL - SSS/DDUV/GEHU - Génétique, Lokhorst, M M, Horbach, S E R, Young-Afat, D A, Stor, M L E, Haverman, L, Spuls, P I, van der Horst, C M A M, Boon, Laurence M., and OVAMA Steering Group

Abstract

The symptoms and appearance of vascular malformations can severely harm a patient's quality of life. The aim of treatment of vascular malformations generally is to improve condition-specific symptoms and/or appearance. Therefore, it is highly important to start testing treatment effects in clinical studies from the patient's perspective. The objective of this study was to develop a patient-reported outcome measure (PROM) for measuring symptoms and appearance in patients with vascular malformations. A first draft of the PROM was based on the previously internationally developed core outcome set. The qualitative part of this study involved interviews with 14 patients, which led to a second draft. The second draft was field-tested cross-sectionally, after which groups of items were evaluated for adequate internal consistency (Cronbach's alpha >0.7) to form composite scores. Construct validity was evaluated by testing 13 predefined hypotheses on known-group differences. The patient interviews ensured adequate content validity and resulted in a general symptom scale with 6 items, head/neck symptom scale with 8 items and an appearance scale with 9 items. Cronbach's alpha was adequate for two composite scores: a general symptom score (0.88) and an appearance score (0.85). Ten out of 13 hypotheses on known-group differences were confirmed, confirming adequate construct validity. With the development of the OVAMA questionnaire, outcomes of patients with vascular malformations can now be evaluated from the patients' perspective. This may help improve the development of evidence-based treatments and the overall care for patients with vascular malformations.

Published
2021

7. Wide-field ultra-narrow-bandpass imaging with the Dragonfly Telephoto Array

Author

Lokhorst, Deborah M., Abraham, Roberto G., van Dokkum, Pieter, Chen, Seery, Lokhorst, Deborah M., Abraham, Roberto G., van Dokkum, Pieter, and Chen, Seery

Abstract

We describe plans for adding a wide-field narrow-band imaging capability to the Dragonfly Telephoto Array. Our plans focus on the development of the `Dragonfly Filter-Tilter', a device which places ultra-narrow bandpass interference filters ($\Delta\lambda \approx 1$ nm) in front of each of the lenses that make up the array. The filters are at the entrance pupil of the optical system, rather than in a converging beam, so their performance is not degraded by a converging light cone. This allows Dragonfly to image with a spectral bandpass that is an order of magnitude narrower than that of telescopes using conventional narrow-band filters, resulting in a large increase in the contrast and detectability of extended low surface brightness line emission. By tilting the filters, the central wavelength of the transmission curve can be tuned over a range of 7 nm, corresponding to a physical distance range of about 20 Mpc of extragalactic targets. A further benefit of our approach is that it allows off-band observations to be obtained at the same time as on-band observations, so systematic errors introduced by rapid sky variability can be removed with high precision. Taken together, these characteristics should give our imaging system the ability to detect extremely faint low-surface brightness line emission. Future versions of the Dragonfly Telephoto Array may have the sensitivity needed to directly image the circumgalactic medium of local galaxies. In this paper, we provide a detailed description of the concept, and present laboratory measurements that are used to verify the key ideas behind the instrument., Comment: 14 pages, 6 figures, SPIE conference proceedings

Published
2020

8. T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells

Author

Pont, Margot J., Oostvogels, Rimke, van Bergen, Cornelis A. M., van der Meijden, EdithD., Honders, Maria W., Bliss, Sophie, Jongsma, Marlieke L. M., Lokhorst, Henk M., Falkenburg, J. H. Frederik, Mutis, Tuna, Griffioen, Marieke, Spaapen, Robbert M., Pont, Margot J., Oostvogels, Rimke, van Bergen, Cornelis A. M., van der Meijden, EdithD., Honders, Maria W., Bliss, Sophie, Jongsma, Marlieke L. M., Lokhorst, Henk M., Falkenburg, J. H. Frederik, Mutis, Tuna, Griffioen, Marieke, and Spaapen, Robbert M.

Published
2019

9. T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells

Author

Pont, Margot J., Oostvogels, Rimke, van Bergen, Cornelis A. M., van der Meijden, EdithD., Honders, Maria W., Bliss, Sophie, Jongsma, Marlieke L. M., Lokhorst, Henk M., Falkenburg, J. H. Frederik, Mutis, Tuna, Griffioen, Marieke, Spaapen, Robbert M., Pont, Margot J., Oostvogels, Rimke, van Bergen, Cornelis A. M., van der Meijden, EdithD., Honders, Maria W., Bliss, Sophie, Jongsma, Marlieke L. M., Lokhorst, Henk M., Falkenburg, J. H. Frederik, Mutis, Tuna, Griffioen, Marieke, and Spaapen, Robbert M.

Published
2019

10. T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells

Author

Pont, Margot J., Oostvogels, Rimke, van Bergen, Cornelis A. M., van der Meijden, EdithD., Honders, Maria W., Bliss, Sophie, Jongsma, Marlieke L. M., Lokhorst, Henk M., Falkenburg, J. H. Frederik, Mutis, Tuna, Griffioen, Marieke, Spaapen, Robbert M., Pont, Margot J., Oostvogels, Rimke, van Bergen, Cornelis A. M., van der Meijden, EdithD., Honders, Maria W., Bliss, Sophie, Jongsma, Marlieke L. M., Lokhorst, Henk M., Falkenburg, J. H. Frederik, Mutis, Tuna, Griffioen, Marieke, and Spaapen, Robbert M.

Published
2019

11. T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells

Author

Infection & Immunity, MS Hematologie, Regenerative Medicine and Stem Cells, Pont, Margot J., Oostvogels, Rimke, van Bergen, Cornelis A. M., van der Meijden, EdithD., Honders, Maria W., Bliss, Sophie, Jongsma, Marlieke L. M., Lokhorst, Henk M., Falkenburg, J. H. Frederik, Mutis, Tuna, Griffioen, Marieke, Spaapen, Robbert M., Infection & Immunity, MS Hematologie, Regenerative Medicine and Stem Cells, Pont, Margot J., Oostvogels, Rimke, van Bergen, Cornelis A. M., van der Meijden, EdithD., Honders, Maria W., Bliss, Sophie, Jongsma, Marlieke L. M., Lokhorst, Henk M., Falkenburg, J. H. Frederik, Mutis, Tuna, Griffioen, Marieke, and Spaapen, Robbert M.

Published
2019

12. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50) : long-term results from the phase 3, randomised controlled trial

Author

van de Donk, Niels WCJ, van der Holt, Bronno, Minnema, Monique C., Vellenga, Edo, Croockewit, Sandra, Kersten, Marie José, von dem Borne, Peter A., Ypma, Paula, Schaafsma, Ron, de Weerdt, Okke, Klein, Saskia K., Delforge, Michel, Levin, Mark David, Bos, Gerard M., Jie, Kon Siong G., Sinnige, Harm, Coenen, Jules LLM, de Waal, Esther G., Zweegman, Sonja, Sonneveld, Pieter, Lokhorst, Henk M., van de Donk, Niels WCJ, van der Holt, Bronno, Minnema, Monique C., Vellenga, Edo, Croockewit, Sandra, Kersten, Marie José, von dem Borne, Peter A., Ypma, Paula, Schaafsma, Ron, de Weerdt, Okke, Klein, Saskia K., Delforge, Michel, Levin, Mark David, Bos, Gerard M., Jie, Kon Siong G., Sinnige, Harm, Coenen, Jules LLM, de Waal, Esther G., Zweegman, Sonja, Sonneveld, Pieter, and Lokhorst, Henk M.

Published
2018

13. Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

Author

Franssen, Laurens E, Nijhof, Inger S, Bjorklund, Chad C, Chiu, Hsiling, Doorn, Ruud, van Velzen, Jeroen, Emmelot, Maarten, van Kessel, Berris, Levin, Mark-David, Bos, Gerard M J, Broijl, Annemiek, Klein, Saskia K, Koene, Harry R, Bloem, Andries C, Beeker, Aart, Faber, Laura M, van der Spek, Ellen, Raymakers, Reinier, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M, Thakurta, Anjan, Qian, Xiaozhong, Mutis, Tuna, van de Donk, Niels W C J, Franssen, Laurens E, Nijhof, Inger S, Bjorklund, Chad C, Chiu, Hsiling, Doorn, Ruud, van Velzen, Jeroen, Emmelot, Maarten, van Kessel, Berris, Levin, Mark-David, Bos, Gerard M J, Broijl, Annemiek, Klein, Saskia K, Koene, Harry R, Bloem, Andries C, Beeker, Aart, Faber, Laura M, van der Spek, Ellen, Raymakers, Reinier, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M, Thakurta, Anjan, Qian, Xiaozhong, Mutis, Tuna, and van de Donk, Niels W C J

Published
2018

14. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50) : long-term results from the phase 3, randomised controlled trial

Author

van de Donk, Niels WCJ, van der Holt, Bronno, Minnema, Monique C., Vellenga, Edo, Croockewit, Sandra, Kersten, Marie José, von dem Borne, Peter A., Ypma, Paula, Schaafsma, Ron, de Weerdt, Okke, Klein, Saskia K., Delforge, Michel, Levin, Mark David, Bos, Gerard M., Jie, Kon Siong G., Sinnige, Harm, Coenen, Jules LLM, de Waal, Esther G., Zweegman, Sonja, Sonneveld, Pieter, Lokhorst, Henk M., van de Donk, Niels WCJ, van der Holt, Bronno, Minnema, Monique C., Vellenga, Edo, Croockewit, Sandra, Kersten, Marie José, von dem Borne, Peter A., Ypma, Paula, Schaafsma, Ron, de Weerdt, Okke, Klein, Saskia K., Delforge, Michel, Levin, Mark David, Bos, Gerard M., Jie, Kon Siong G., Sinnige, Harm, Coenen, Jules LLM, de Waal, Esther G., Zweegman, Sonja, Sonneveld, Pieter, and Lokhorst, Henk M.

Published
2018

15. Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

Author

Franssen, Laurens E, Nijhof, Inger S, Bjorklund, Chad C, Chiu, Hsiling, Doorn, Ruud, van Velzen, Jeroen, Emmelot, Maarten, van Kessel, Berris, Levin, Mark-David, Bos, Gerard M J, Broijl, Annemiek, Klein, Saskia K, Koene, Harry R, Bloem, Andries C, Beeker, Aart, Faber, Laura M, van der Spek, Ellen, Raymakers, Reinier, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M, Thakurta, Anjan, Qian, Xiaozhong, Mutis, Tuna, van de Donk, Niels W C J, Franssen, Laurens E, Nijhof, Inger S, Bjorklund, Chad C, Chiu, Hsiling, Doorn, Ruud, van Velzen, Jeroen, Emmelot, Maarten, van Kessel, Berris, Levin, Mark-David, Bos, Gerard M J, Broijl, Annemiek, Klein, Saskia K, Koene, Harry R, Bloem, Andries C, Beeker, Aart, Faber, Laura M, van der Spek, Ellen, Raymakers, Reinier, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M, Thakurta, Anjan, Qian, Xiaozhong, Mutis, Tuna, and van de Donk, Niels W C J

Published
2018

16. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial

Author

Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., Kooy, M. van Marwijk, Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, Le, Salwender, H. J., Sonneveld, P., Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., Kooy, M. van Marwijk, Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, Le, Salwender, H. J., and Sonneveld, P.

Abstract

The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR) = 0.76, 95% confidence interval (95% CI) of 0.65-0.89, P = 0.001). Overall survival (OS) was similar in the PAD versus VAD arm (HR = 0.89, 95% CI: 0.74-1.08, P = 0.24). The incidence of SPM were similar between the two arms (7% each, P = 0.73). The negative prognostic effects of the cytogenetic aberration deletion 17p13 (clone size >= 10%) and renal impairment at baseline (serum creatinine > 2 mg dl(-1)) on PFS and OS remained abrogated in the PAD but not VAD arm. OS from first relapse/progression was similar between the study arms (HR = 1.02, P = 0.85). In conclusion, the survival benefit with BTZ induction/maintenance compared with classical cytotoxic agents and thalidomide maintenance is maintained without an increased risk of SPM.

Published
2018

17. Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trail - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal

Author

Seckinger, Anja, Salwender, Hans Juergen, Martin, Hans, Scheid, Christof, Hielscher, Thomas, Bertsch, Uta, Hummel, Manuela, Jauch, Anna, Knauf, Wolfgang, Emde, Martina, Beck, Susanne, Neben, Kai, Lokhorst, Henk M., van der Holt, Bronno, Duehrsen, Ulrich, Duerig, Jan, Lindemann, Hans-Walter, Schmidt-Wolf, Ingo, Haenel, Mathias, Lathan, Bernd, Raab, Marc S., Mueller-Tidow, Carsten, Sonneveld, Pieter, Blau, Igor Wolfgang, Hillengass, Jens, Weisel, Katja, Goldschmidt, Hartmut, Hose, Dirk, Seckinger, Anja, Salwender, Hans Juergen, Martin, Hans, Scheid, Christof, Hielscher, Thomas, Bertsch, Uta, Hummel, Manuela, Jauch, Anna, Knauf, Wolfgang, Emde, Martina, Beck, Susanne, Neben, Kai, Lokhorst, Henk M., van der Holt, Bronno, Duehrsen, Ulrich, Duerig, Jan, Lindemann, Hans-Walter, Schmidt-Wolf, Ingo, Haenel, Mathias, Lathan, Bernd, Raab, Marc S., Mueller-Tidow, Carsten, Sonneveld, Pieter, Blau, Igor Wolfgang, Hillengass, Jens, Weisel, Katja, Goldschmidt, Hartmut, and Hose, Dirk

Published
2018

18. Bortezomib before and after high-dose therapy in myeloma : long-term results from the phase III HOVON-65/GMMG-HD4 trial

Author

Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, Sonneveld, P, Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, and Sonneveld, P

Published
2018

19. Bortezomib before and after high-dose therapy in myeloma : long-term results from the phase III HOVON-65/GMMG-HD4 trial

Author

Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, Sonneveld, P, Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, and Sonneveld, P

Published
2018

20. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50) : long-term results from the phase 3, randomised controlled trial

Author

van de Donk, Niels WCJ, van der Holt, Bronno, Minnema, Monique C., Vellenga, Edo, Croockewit, Sandra, Kersten, Marie José, von dem Borne, Peter A., Ypma, Paula, Schaafsma, Ron, de Weerdt, Okke, Klein, Saskia K., Delforge, Michel, Levin, Mark David, Bos, Gerard M., Jie, Kon Siong G., Sinnige, Harm, Coenen, Jules LLM, de Waal, Esther G., Zweegman, Sonja, Sonneveld, Pieter, Lokhorst, Henk M., van de Donk, Niels WCJ, van der Holt, Bronno, Minnema, Monique C., Vellenga, Edo, Croockewit, Sandra, Kersten, Marie José, von dem Borne, Peter A., Ypma, Paula, Schaafsma, Ron, de Weerdt, Okke, Klein, Saskia K., Delforge, Michel, Levin, Mark David, Bos, Gerard M., Jie, Kon Siong G., Sinnige, Harm, Coenen, Jules LLM, de Waal, Esther G., Zweegman, Sonja, Sonneveld, Pieter, and Lokhorst, Henk M.

Published
2018

21. Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

Author

Franssen, Laurens E, Nijhof, Inger S, Bjorklund, Chad C, Chiu, Hsiling, Doorn, Ruud, van Velzen, Jeroen, Emmelot, Maarten, van Kessel, Berris, Levin, Mark-David, Bos, Gerard M J, Broijl, Annemiek, Klein, Saskia K, Koene, Harry R, Bloem, Andries C, Beeker, Aart, Faber, Laura M, van der Spek, Ellen, Raymakers, Reinier, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M, Thakurta, Anjan, Qian, Xiaozhong, Mutis, Tuna, van de Donk, Niels W C J, Franssen, Laurens E, Nijhof, Inger S, Bjorklund, Chad C, Chiu, Hsiling, Doorn, Ruud, van Velzen, Jeroen, Emmelot, Maarten, van Kessel, Berris, Levin, Mark-David, Bos, Gerard M J, Broijl, Annemiek, Klein, Saskia K, Koene, Harry R, Bloem, Andries C, Beeker, Aart, Faber, Laura M, van der Spek, Ellen, Raymakers, Reinier, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M, Thakurta, Anjan, Qian, Xiaozhong, Mutis, Tuna, and van de Donk, Niels W C J

Published
2018

22. Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

Author

Unit Opleiding Aios, CTI Kuball, Regenerative Medicine and Stem Cells, CTI CFF, Infection & Immunity, CDL Patiëntenzorg MI, CDL Celdiagnostiek, MS Hematologie, Other research (not in main researchprogram), Externen Hematologie, CDL Cluster Onderzoek en Onderwijs, Franssen, Laurens E, Nijhof, Inger S, Bjorklund, Chad C, Chiu, Hsiling, Doorn, Ruud, van Velzen, Jeroen, Emmelot, Maarten, van Kessel, Berris, Levin, Mark-David, Bos, Gerard M J, Broijl, Annemiek, Klein, Saskia K, Koene, Harry R, Bloem, Andries C, Beeker, Aart, Faber, Laura M, van der Spek, Ellen, Raymakers, Reinier, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M, Thakurta, Anjan, Qian, Xiaozhong, Mutis, Tuna, van de Donk, Niels W C J, Unit Opleiding Aios, CTI Kuball, Regenerative Medicine and Stem Cells, CTI CFF, Infection & Immunity, CDL Patiëntenzorg MI, CDL Celdiagnostiek, MS Hematologie, Other research (not in main researchprogram), Externen Hematologie, CDL Cluster Onderzoek en Onderwijs, Franssen, Laurens E, Nijhof, Inger S, Bjorklund, Chad C, Chiu, Hsiling, Doorn, Ruud, van Velzen, Jeroen, Emmelot, Maarten, van Kessel, Berris, Levin, Mark-David, Bos, Gerard M J, Broijl, Annemiek, Klein, Saskia K, Koene, Harry R, Bloem, Andries C, Beeker, Aart, Faber, Laura M, van der Spek, Ellen, Raymakers, Reinier, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M, Thakurta, Anjan, Qian, Xiaozhong, Mutis, Tuna, and van de Donk, Niels W C J

Published
2018

23. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, van de Donk, Niels WCJ, van der Holt, Bronno, Minnema, Monique C., Vellenga, Edo, Croockewit, Sandra, Kersten, Marie José, von dem Borne, Peter A., Ypma, Paula, Schaafsma, Ron, de Weerdt, Okke, Klein, Saskia K., Delforge, Michel, Levin, Mark David, Bos, Gerard M., Jie, Kon Siong G., Sinnige, Harm, Coenen, Jules LLM, de Waal, Esther G., Zweegman, Sonja, Sonneveld, Pieter, Lokhorst, Henk M., MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, van de Donk, Niels WCJ, van der Holt, Bronno, Minnema, Monique C., Vellenga, Edo, Croockewit, Sandra, Kersten, Marie José, von dem Borne, Peter A., Ypma, Paula, Schaafsma, Ron, de Weerdt, Okke, Klein, Saskia K., Delforge, Michel, Levin, Mark David, Bos, Gerard M., Jie, Kon Siong G., Sinnige, Harm, Coenen, Jules LLM, de Waal, Esther G., Zweegman, Sonja, Sonneveld, Pieter, and Lokhorst, Henk M.

Published
2018

24. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

Author

Externen Hematologie, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, Sonneveld, P, Externen Hematologie, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, and Sonneveld, P

Published
2018

25. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial

Author

Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., Kooy, M. van Marwijk, Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, Le, Salwender, H. J., Sonneveld, P., Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., Kooy, M. van Marwijk, Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, Le, Salwender, H. J., and Sonneveld, P.

Abstract

The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial compared bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm) compared with classical cytotoxic agents prior and thalidomide after HDM (VAD arm) in multiple myeloma (MM) patients aged 18-65 years. Here, the long-term follow-up and data on second primary malignancies (SPM) are presented. After a median follow-up of 96 months, progression-free survival (censored at allogeneic transplantation, PFS) remained significantly prolonged in the PAD versus VAD arm (hazard ratio (HR) = 0.76, 95% confidence interval (95% CI) of 0.65-0.89, P = 0.001). Overall survival (OS) was similar in the PAD versus VAD arm (HR = 0.89, 95% CI: 0.74-1.08, P = 0.24). The incidence of SPM were similar between the two arms (7% each, P = 0.73). The negative prognostic effects of the cytogenetic aberration deletion 17p13 (clone size >= 10%) and renal impairment at baseline (serum creatinine > 2 mg dl(-1)) on PFS and OS remained abrogated in the PAD but not VAD arm. OS from first relapse/progression was similar between the study arms (HR = 1.02, P = 0.85). In conclusion, the survival benefit with BTZ induction/maintenance compared with classical cytotoxic agents and thalidomide maintenance is maintained without an increased risk of SPM.

Published
2018

26. Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trail - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal

Author

Seckinger, Anja, Salwender, Hans Juergen, Martin, Hans, Scheid, Christof, Hielscher, Thomas, Bertsch, Uta, Hummel, Manuela, Jauch, Anna, Knauf, Wolfgang, Emde, Martina, Beck, Susanne, Neben, Kai, Lokhorst, Henk M., van der Holt, Bronno, Duehrsen, Ulrich, Duerig, Jan, Lindemann, Hans-Walter, Schmidt-Wolf, Ingo, Haenel, Mathias, Lathan, Bernd, Raab, Marc S., Mueller-Tidow, Carsten, Sonneveld, Pieter, Blau, Igor Wolfgang, Hillengass, Jens, Weisel, Katja, Goldschmidt, Hartmut, Hose, Dirk, Seckinger, Anja, Salwender, Hans Juergen, Martin, Hans, Scheid, Christof, Hielscher, Thomas, Bertsch, Uta, Hummel, Manuela, Jauch, Anna, Knauf, Wolfgang, Emde, Martina, Beck, Susanne, Neben, Kai, Lokhorst, Henk M., van der Holt, Bronno, Duehrsen, Ulrich, Duerig, Jan, Lindemann, Hans-Walter, Schmidt-Wolf, Ingo, Haenel, Mathias, Lathan, Bernd, Raab, Marc S., Mueller-Tidow, Carsten, Sonneveld, Pieter, Blau, Igor Wolfgang, Hillengass, Jens, Weisel, Katja, Goldschmidt, Hartmut, and Hose, Dirk

Published
2018

27. Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients

Author

Oostvogels, R., Kneppers, E., Minnema, M. C., Doorn, R. C., Franssen, L. E., Aarts, T., Emmelot, M. E., Spierings, E., Slaper-Cortenbach, I., Westinga, K., Goulmy, E., Lokhorst, H. M., Mutis, T., Oostvogels, R., Kneppers, E., Minnema, M. C., Doorn, R. C., Franssen, L. E., Aarts, T., Emmelot, M. E., Spierings, E., Slaper-Cortenbach, I., Westinga, K., Goulmy, E., Lokhorst, H. M., and Mutis, T.

Published
2017

28. Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients

Author

Oostvogels, R., Kneppers, E., Minnema, M. C., Doorn, R. C., Franssen, L. E., Aarts, T., Emmelot, M. E., Spierings, E., Slaper-Cortenbach, I., Westinga, K., Goulmy, E., Lokhorst, H. M., Mutis, T., Oostvogels, R., Kneppers, E., Minnema, M. C., Doorn, R. C., Franssen, L. E., Aarts, T., Emmelot, M. E., Spierings, E., Slaper-Cortenbach, I., Westinga, K., Goulmy, E., Lokhorst, H. M., and Mutis, T.

Published
2017

29. Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients

Author

Oostvogels, R., Kneppers, E., Minnema, M. C., Doorn, R. C., Franssen, L. E., Aarts, T., Emmelot, M. E., Spierings, E., Slaper-Cortenbach, I., Westinga, K., Goulmy, E., Lokhorst, H. M., Mutis, T., Oostvogels, R., Kneppers, E., Minnema, M. C., Doorn, R. C., Franssen, L. E., Aarts, T., Emmelot, M. E., Spierings, E., Slaper-Cortenbach, I., Westinga, K., Goulmy, E., Lokhorst, H. M., and Mutis, T.

Published
2017

30. Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients

Author

Unit Opleiding Aios, MS Hematologie, Regenerative Medicine and Stem Cells, Infection & Immunity, CTI Kuball, CDL Celdiagnostiek, Apotheek Celtherapie Faciliteit, Externen Hematologie, CDL Cluster Onderzoek en Onderwijs, Oostvogels, R., Kneppers, E., Minnema, M. C., Doorn, R. C., Franssen, L. E., Aarts, T., Emmelot, M. E., Spierings, E., Slaper-Cortenbach, I., Westinga, K., Goulmy, E., Lokhorst, H. M., Mutis, T., Unit Opleiding Aios, MS Hematologie, Regenerative Medicine and Stem Cells, Infection & Immunity, CTI Kuball, CDL Celdiagnostiek, Apotheek Celtherapie Faciliteit, Externen Hematologie, CDL Cluster Onderzoek en Onderwijs, Oostvogels, R., Kneppers, E., Minnema, M. C., Doorn, R. C., Franssen, L. E., Aarts, T., Emmelot, M. E., Spierings, E., Slaper-Cortenbach, I., Westinga, K., Goulmy, E., Lokhorst, H. M., and Mutis, T.

Published
2017

31. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Author

Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C, Lassen, Ulrik Niels, Laubach, Jacob P, Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A Kate, Guckert, Mary E, de Boer, Carla, Khokhar, Nushmia Z, Yeh, Howard, Clemens, Pamela L, Ahmadi, Tahamtan, Lokhorst, Henk M, Richardson, Paul G, Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C, Lassen, Ulrik Niels, Laubach, Jacob P, Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A Kate, Guckert, Mary E, de Boer, Carla, Khokhar, Nushmia Z, Yeh, Howard, Clemens, Pamela L, Ahmadi, Tahamtan, Lokhorst, Henk M, and Richardson, Paul G

Published
2016

32. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Author

Drent, Esther, Groen, Richard W.J., Noort, Willy A, Themeli, Maria, Lammerts van Bueren, Jeroen J, Parren, Paul W H I, Kuball, Jürgen, Sebestyen, Zsolt, Yuan, Huipin, de Bruijn, Joost, van de Donk, Niels W C J, Martens, Anton C M, Lokhorst, Henk M, Mutis, Tuna, Drent, Esther, Groen, Richard W.J., Noort, Willy A, Themeli, Maria, Lammerts van Bueren, Jeroen J, Parren, Paul W H I, Kuball, Jürgen, Sebestyen, Zsolt, Yuan, Huipin, de Bruijn, Joost, van de Donk, Niels W C J, Martens, Anton C M, Lokhorst, Henk M, and Mutis, Tuna

Published
2016

33. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Author

Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C, Lassen, Ulrik, Laubach, Jacob P, Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A Kate, Guckert, Mary E, de Boer, Carla, Khokhar, Nushmia Z, Yeh, Howard, Clemens, Pamela L, Ahmadi, Tahamtan, Lokhorst, Henk M, Richardson, Paul G, Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C, Lassen, Ulrik, Laubach, Jacob P, Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A Kate, Guckert, Mary E, de Boer, Carla, Khokhar, Nushmia Z, Yeh, Howard, Clemens, Pamela L, Ahmadi, Tahamtan, Lokhorst, Henk M, and Richardson, Paul G

Published
2016

35. Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance

Author

de Haart, Sanne J, Holthof, Lisa, Noort, Willy A, Minnema, Monique C, Emmelot, Maarten E, Aarts-Riemens, Tineke, Doshi, Parul, Sasser, Kate, Yuan, Huipin, de Bruijn, Joost, Martens, Anton C M, van de Donk, Niels W C J, Lokhorst, Henk M, Groen, Richard W J, Mutis, Tuna, de Haart, Sanne J, Holthof, Lisa, Noort, Willy A, Minnema, Monique C, Emmelot, Maarten E, Aarts-Riemens, Tineke, Doshi, Parul, Sasser, Kate, Yuan, Huipin, de Bruijn, Joost, Martens, Anton C M, van de Donk, Niels W C J, Lokhorst, Henk M, Groen, Richard W J, and Mutis, Tuna

Published
2016

36. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Author

Nijhof, Inger S, Casneuf, Tineke, van Velzen, Jeroen, van Kessel, Berris, Axel, Amy E, Syed, Khaja, Groen, Richard W J, van Duin, Mark, Sonneveld, Pieter, Minnema, Monique C, Zweegman, Sonja, Chiu, Christopher, Bloem, Andries C, Mutis, Tuna, Lokhorst, Henk M, Sasser, A Kate, van de Donk, Niels W C J, Nijhof, Inger S, Casneuf, Tineke, van Velzen, Jeroen, van Kessel, Berris, Axel, Amy E, Syed, Khaja, Groen, Richard W J, van Duin, Mark, Sonneveld, Pieter, Minnema, Monique C, Zweegman, Sonja, Chiu, Christopher, Bloem, Andries C, Mutis, Tuna, Lokhorst, Henk M, Sasser, A Kate, and van de Donk, Niels W C J

Published
2016

38. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Author

Drent, Esther, Groen, Richard W.J., Noort, Willy A, Themeli, Maria, Lammerts van Bueren, Jeroen J, Parren, Paul W H I, Kuball, Jürgen, Sebestyen, Zsolt, Yuan, Huipin, de Bruijn, Joost, van de Donk, Niels W C J, Martens, Anton C M, Lokhorst, Henk M, Mutis, Tuna, Drent, Esther, Groen, Richard W.J., Noort, Willy A, Themeli, Maria, Lammerts van Bueren, Jeroen J, Parren, Paul W H I, Kuball, Jürgen, Sebestyen, Zsolt, Yuan, Huipin, de Bruijn, Joost, van de Donk, Niels W C J, Martens, Anton C M, Lokhorst, Henk M, and Mutis, Tuna

Published
2016

39. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Author

Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C, Lassen, Ulrik, Laubach, Jacob P, Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A Kate, Guckert, Mary E, de Boer, Carla, Khokhar, Nushmia Z, Yeh, Howard, Clemens, Pamela L, Ahmadi, Tahamtan, Lokhorst, Henk M, Richardson, Paul G, Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C, Lassen, Ulrik, Laubach, Jacob P, Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A Kate, Guckert, Mary E, de Boer, Carla, Khokhar, Nushmia Z, Yeh, Howard, Clemens, Pamela L, Ahmadi, Tahamtan, Lokhorst, Henk M, and Richardson, Paul G

Published
2016

40. Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance

Author

de Haart, Sanne J, Holthof, Lisa, Noort, Willy A, Minnema, Monique C, Emmelot, Maarten E, Aarts-Riemens, Tineke, Doshi, Parul, Sasser, Kate, Yuan, Huipin, de Bruijn, Joost, Martens, Anton C M, van de Donk, Niels W C J, Lokhorst, Henk M, Groen, Richard W J, Mutis, Tuna, de Haart, Sanne J, Holthof, Lisa, Noort, Willy A, Minnema, Monique C, Emmelot, Maarten E, Aarts-Riemens, Tineke, Doshi, Parul, Sasser, Kate, Yuan, Huipin, de Bruijn, Joost, Martens, Anton C M, van de Donk, Niels W C J, Lokhorst, Henk M, Groen, Richard W J, and Mutis, Tuna

Published
2016

43. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Author

Nijhof, Inger S, Casneuf, Tineke, van Velzen, Jeroen, van Kessel, Berris, Axel, Amy E, Syed, Khaja, Groen, Richard W J, van Duin, Mark, Sonneveld, Pieter, Minnema, Monique C, Zweegman, Sonja, Chiu, Christopher, Bloem, Andries C, Mutis, Tuna, Lokhorst, Henk M, Sasser, A Kate, van de Donk, Niels W C J, Nijhof, Inger S, Casneuf, Tineke, van Velzen, Jeroen, van Kessel, Berris, Axel, Amy E, Syed, Khaja, Groen, Richard W J, van Duin, Mark, Sonneveld, Pieter, Minnema, Monique C, Zweegman, Sonja, Chiu, Christopher, Bloem, Andries C, Mutis, Tuna, Lokhorst, Henk M, Sasser, A Kate, and van de Donk, Niels W C J

Published
2016

45. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Author

Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C, Lassen, Ulrik, Laubach, Jacob P, Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A Kate, Guckert, Mary E, de Boer, Carla, Khokhar, Nushmia Z, Yeh, Howard, Clemens, Pamela L, Ahmadi, Tahamtan, Lokhorst, Henk M, Richardson, Paul G, Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C, Lassen, Ulrik, Laubach, Jacob P, Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A Kate, Guckert, Mary E, de Boer, Carla, Khokhar, Nushmia Z, Yeh, Howard, Clemens, Pamela L, Ahmadi, Tahamtan, Lokhorst, Henk M, and Richardson, Paul G

Published
2016

46. Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance

Author

de Haart, Sanne J, Holthof, Lisa, Noort, Willy A, Minnema, Monique C, Emmelot, Maarten E, Aarts-Riemens, Tineke, Doshi, Parul, Sasser, Kate, Yuan, Huipin, de Bruijn, Joost, Martens, Anton C M, van de Donk, Niels W C J, Lokhorst, Henk M, Groen, Richard W J, Mutis, Tuna, de Haart, Sanne J, Holthof, Lisa, Noort, Willy A, Minnema, Monique C, Emmelot, Maarten E, Aarts-Riemens, Tineke, Doshi, Parul, Sasser, Kate, Yuan, Huipin, de Bruijn, Joost, Martens, Anton C M, van de Donk, Niels W C J, Lokhorst, Henk M, Groen, Richard W J, and Mutis, Tuna

Published
2016

47. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Author

Nijhof, Inger S, Casneuf, Tineke, van Velzen, Jeroen, van Kessel, Berris, Axel, Amy E, Syed, Khaja, Groen, Richard W J, van Duin, Mark, Sonneveld, Pieter, Minnema, Monique C, Zweegman, Sonja, Chiu, Christopher, Bloem, Andries C, Mutis, Tuna, Lokhorst, Henk M, Sasser, A Kate, van de Donk, Niels W C J, Nijhof, Inger S, Casneuf, Tineke, van Velzen, Jeroen, van Kessel, Berris, Axel, Amy E, Syed, Khaja, Groen, Richard W J, van Duin, Mark, Sonneveld, Pieter, Minnema, Monique C, Zweegman, Sonja, Chiu, Christopher, Bloem, Andries C, Mutis, Tuna, Lokhorst, Henk M, Sasser, A Kate, and van de Donk, Niels W C J

Published
2016

49. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Author

Drent, Esther, Groen, Richard W.J., Noort, Willy A, Themeli, Maria, Lammerts van Bueren, Jeroen J, Parren, Paul W H I, Kuball, Jürgen, Sebestyen, Zsolt, Yuan, Huipin, de Bruijn, Joost, van de Donk, Niels W C J, Martens, Anton C M, Lokhorst, Henk M, Mutis, Tuna, Drent, Esther, Groen, Richard W.J., Noort, Willy A, Themeli, Maria, Lammerts van Bueren, Jeroen J, Parren, Paul W H I, Kuball, Jürgen, Sebestyen, Zsolt, Yuan, Huipin, de Bruijn, Joost, van de Donk, Niels W C J, Martens, Anton C M, Lokhorst, Henk M, and Mutis, Tuna

Published
2016

50. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Author

CTI Kuball, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Drent, Esther, Groen, Richard W.J., Noort, Willy A, Themeli, Maria, Lammerts van Bueren, Jeroen J, Parren, Paul W H I, Kuball, Jürgen, Sebestyen, Zsolt, Yuan, Huipin, de Bruijn, Joost, van de Donk, Niels W C J, Martens, Anton C M, Lokhorst, Henk M, Mutis, Tuna, CTI Kuball, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Drent, Esther, Groen, Richard W.J., Noort, Willy A, Themeli, Maria, Lammerts van Bueren, Jeroen J, Parren, Paul W H I, Kuball, Jürgen, Sebestyen, Zsolt, Yuan, Huipin, de Bruijn, Joost, van de Donk, Niels W C J, Martens, Anton C M, Lokhorst, Henk M, and Mutis, Tuna

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results